Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines
Journal
Hepatology international
Journal Volume
18
Journal Issue
3
Start Page
1066
End Page
1066
Date Issued
2024-01-22
Author(s)
Teng, Wei
Chang, Ting-Tsung
Yang, Hwai-I
Peng, Cheng-Yuan
Su, Chien-Wei
Hu, Tsung-Hui
Yu, Ming-Lung
Wu, Jaw-Ching
Abstract
Authors would like to add below funding information to their publication. This study was supported by funding from Ministry of Science and Technology (National Science and Technology Council) (104-2314-B-182A-048-MY3; 110-2314-B-A49A-505; 110-2314-B-075-010-MY3), VGHUST Joint Research Program, Tsou Foundation (VGHUST110-G7-3-3), VGHTPE Research Program (V107C-161, V108C-059 and V109C-049), Ministry of Health and Welfare (MOHW107-TDU-B-211-114019; 108-TDU-B-211-124019; 109-TDU-B-211-134019; 110-TDU-B-211-144019) and Cancer Progression Research Center, National Yang-Ming University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education. The original article has been corrected.
Type
corrigendum